Status:
COMPLETED
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test whether sunitinib (SU011248) has activity and is safe in patients with renal cell carcinoma (RCC) who have failed prior therapy with bevacizumab (Avastin) -based t...
Eligibility Criteria
Inclusion
- Histologically proven renal cell carcinoma of clear cell histology with metastases
- Evidence of measurable disease
- Radiographic evidence of disease progression during or within 3 months of completion of bevacizumab-based treatment
- Prior radical or partial nephrectomy
Exclusion
- Prior treatment with any other anti-angiogenic therapy other than bevacizumab
- Prior systemic treatment for RCC \> 2 regimens
- History of or known brain metastases
- Serious acute or chronic illness or recent history of significant cardiac abnormality
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00089648
Start Date
December 1 2004
End Date
March 1 2008
Last Update
January 12 2010
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Duarte, California, United States, 91010
2
Pfizer Investigational Site
Pasadena, California, United States, 91105
3
Pfizer Investigational Site
San Francisco, California, United States, 94115
4
Pfizer Investigational Site
Chicago, Illinois, United States, 60637-1460